Cargando…

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination

The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Hamad, Alterki, Abdulmohsen, Sindhu, Sardar, Alahmad, Barrak, Hammad, Maha, Al-Sabah, Salman, Alghounaim, Mohammad, Jamal, Mohammad H., Aldei, Ali, Mairza, Mohammad J., Husain, Maitham, Deverajan, Sriraman, Ahmad, Rasheed, Cherian, Preethi, Alkhairi, Irina, Alkandari, Abdullah, Abubaker, Jehad, Abu-Farha, Mohamed, Al-Mulla, Fahd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652288/
https://www.ncbi.nlm.nih.gov/pubmed/34899701
http://dx.doi.org/10.3389/fimmu.2021.752233
_version_ 1784611564395954176
author Ali, Hamad
Alterki, Abdulmohsen
Sindhu, Sardar
Alahmad, Barrak
Hammad, Maha
Al-Sabah, Salman
Alghounaim, Mohammad
Jamal, Mohammad H.
Aldei, Ali
Mairza, Mohammad J.
Husain, Maitham
Deverajan, Sriraman
Ahmad, Rasheed
Cherian, Preethi
Alkhairi, Irina
Alkandari, Abdullah
Abubaker, Jehad
Abu-Farha, Mohamed
Al-Mulla, Fahd
author_facet Ali, Hamad
Alterki, Abdulmohsen
Sindhu, Sardar
Alahmad, Barrak
Hammad, Maha
Al-Sabah, Salman
Alghounaim, Mohammad
Jamal, Mohammad H.
Aldei, Ali
Mairza, Mohammad J.
Husain, Maitham
Deverajan, Sriraman
Ahmad, Rasheed
Cherian, Preethi
Alkhairi, Irina
Alkandari, Abdullah
Abubaker, Jehad
Abu-Farha, Mohamed
Al-Mulla, Fahd
author_sort Ali, Hamad
collection PubMed
description The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1 vs. 138 ± 59.4 BAU/ml for IgG and 87.1 ± 11.6 vs. 79.7 ± 19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection, and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95% CI: 27.08 to 0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: 8.53 to 0.32%, p=0.036) fewer neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity. Nonetheless, it is important that people get their COVID-19 vaccination especially people with diabetes.
format Online
Article
Text
id pubmed-8652288
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86522882021-12-09 Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination Ali, Hamad Alterki, Abdulmohsen Sindhu, Sardar Alahmad, Barrak Hammad, Maha Al-Sabah, Salman Alghounaim, Mohammad Jamal, Mohammad H. Aldei, Ali Mairza, Mohammad J. Husain, Maitham Deverajan, Sriraman Ahmad, Rasheed Cherian, Preethi Alkhairi, Irina Alkandari, Abdullah Abubaker, Jehad Abu-Farha, Mohamed Al-Mulla, Fahd Front Immunol Immunology The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1 vs. 138 ± 59.4 BAU/ml for IgG and 87.1 ± 11.6 vs. 79.7 ± 19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection, and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95% CI: 27.08 to 0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: 8.53 to 0.32%, p=0.036) fewer neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity. Nonetheless, it is important that people get their COVID-19 vaccination especially people with diabetes. Frontiers Media S.A. 2021-11-24 /pmc/articles/PMC8652288/ /pubmed/34899701 http://dx.doi.org/10.3389/fimmu.2021.752233 Text en Copyright © 2021 Ali, Alterki, Sindhu, Alahmad, Hammad, Al-Sabah, Alghounaim, Jamal, Aldei, Mairza, Husain, Deverajan, Ahmad, Cherian, Alkhairi, Alkandari, Abubaker, Abu-Farha and Al-Mulla https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ali, Hamad
Alterki, Abdulmohsen
Sindhu, Sardar
Alahmad, Barrak
Hammad, Maha
Al-Sabah, Salman
Alghounaim, Mohammad
Jamal, Mohammad H.
Aldei, Ali
Mairza, Mohammad J.
Husain, Maitham
Deverajan, Sriraman
Ahmad, Rasheed
Cherian, Preethi
Alkhairi, Irina
Alkandari, Abdullah
Abubaker, Jehad
Abu-Farha, Mohamed
Al-Mulla, Fahd
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
title Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
title_full Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
title_fullStr Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
title_full_unstemmed Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
title_short Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
title_sort robust antibody levels in both diabetic and non-diabetic individuals after bnt162b2 mrna covid-19 vaccination
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652288/
https://www.ncbi.nlm.nih.gov/pubmed/34899701
http://dx.doi.org/10.3389/fimmu.2021.752233
work_keys_str_mv AT alihamad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT alterkiabdulmohsen robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT sindhusardar robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT alahmadbarrak robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT hammadmaha robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT alsabahsalman robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT alghounaimmohammad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT jamalmohammadh robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT aldeiali robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT mairzamohammadj robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT husainmaitham robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT deverajansriraman robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT ahmadrasheed robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT cherianpreethi robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT alkhairiirina robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT alkandariabdullah robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT abubakerjehad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT abufarhamohamed robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination
AT almullafahd robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination